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ABSTRACT The bek gene encodes a member of the high-
affinity fibroblast growth factor receptor family. The
BEK/FGFR-2 receptor is a membrane-snning tyrosine ki-
nase with the typical features ofFGF receptors. We have cloned
a murine bek cDNA and expressed it in receptor-negative
Chinese hamster ovary cells and in 32D myeloid cells. The BEK
receptor expressed in Chinese hamster ovary cells binds acidic
FGF, basic FGF, and Kaposi FGF equally well but does not
bind keratinocyte growth factor or FGF-5 appreciably. Upon
treatment with basic FGF or Kaposi FGF, the BEK receptor is
phosphorylated and a mitogenic response is achieved. Heparan
sulfate proteoglycans have been shown to play an obligate role
in basic FGF binding to the high-affinity FLG receptor. Unlike
the BEK-expressing Chinese hamster ovary cells, 32D cells
expressing the BEK receptor require the addition of exogenous
heparin in order to grow in the presence of basic FGF or Kaposi
FGF. We show that the addition of heparin greatly enhances
the binding of radio-labeled basic FGF to the receptor. Thus
the BEK receptor, like FLG, also requires an interaction with
heparan sulfate proteoglycans to facilitate binding to its li-
gands.
Fibroblast growth factors (FGFs) are a family of seven
heparin-binding polypeptides that share 30-40% homology
(1). Like other growth factors, FGFs act by binding and
activating specific cell-surface receptors, and the FGF re-
ceptors also represent a family of related, but distinct,
membrane-spanning tyrosine kinases. Four such FGF recep-
tors have thus far been cloned. These include the FLG
receptor or FGFR-1 (2-5), the BEK receptor or FGFR-2
(6-10), FGFR-3 (10, 11), and, recently, a human FGFR-4
(12). Related receptors capable of binding bFGF have also
been described in Xenopus and Drosophila (13, 14).
Each of these receptors consists of an extracellular ligand
binding region containing three immunoglobulin-like do-
mains (15) and an intracellular split tyrosine kinase domain.
The FLG and BEK receptors are most closely related and
bind acidic FGF (aFGF) and basic FGF (bFGF) with equal
affinities (7, 16). FGFR-3 has also been shown to bind both
growth factors (11), whereas FGFR-4 binds aFGF but not
bFGF (12), thus providing one example of strict ligand
specificity in this receptor family. The FLG receptor binds
Kaposi FGF (K-FGF) with - 15x lower affinity than aFGF
or bFGF (5).
In addition to multiple receptors for the FGF family,
variant forms of FLG and BEK have been described that
probably arise from alternative RNA splicing, thereby in-
creasing the complexity of this receptor family (4, 16, 17). A
shorter form of FLG, which is missing the N-terminal,
immunoglobulin-like domain, binds with high affinity to
aFGF, bFGF, and K-FGF, indicating that the first immuno-
globulin-like domain of the receptor is dispensable for ligand
binding (5, 16). An isoform of BEK, which results from
alternative splicing, was cloned from a keratinocyte expres-
sion library as a receptor for keratinocyte growth factor
(KGF) (17). It binds aFGF and KGF with high affinity but
exhibits very low affinity for bFGF (17). Adding another
dimension to FGF-receptor interaction are the low-affinity
FGF receptors or heparan sulfate proteoglycans (HSPGs),
which have been shown to play an essential role in the binding
of bFGF to FLG (18) and in bFGF-mediated fibroblast
growth and myoblast differentiation (19).
Since the FGFs seem to interact with only partial speci-
ficity with a family of receptor tyrosine kinases, which are
often coexpressed in the same cells, the question arises of
why such a degree ofredundancy exists in this system. A first
step necessary to answer this question is the precise char-
acterization of each of the FGF receptors, its binding spec-
ificity, and the factors required for its activation. In this
report we describe the cloning and characterization of a
three-immunoglobulin-domain form of murine BEK. This
receptor, when expressed in Chinese hamster ovary (CHO)
cells, is capable of binding aFGF, bFGF, and K-FGF with
equal affinity but does not bind KGF or FGF-5 appreciably.
The BEK receptor is phosphorylated in response to the three
former factors, and a proliferative response is elicited. When
BEK is introduced in the 32D myeloid cell line, which is
normally interleukin 3 (IL-3) dependent (20) and does not
appear to express high- or low-affinity FGF receptors, the
cells can respond to FGFs instead of IL-3, but only in the
presence of exogenous heparin. In the presence of heparin,
the binding of 1'I-labeled bFGF (125I-bFGF) to the BEK
receptor is dramatically enhanced, indicating that this recep-
tor also requires HSPGs to facilitate ligand binding.¶
MATERIALS AND METHODS
Library Screening and Sequencing. A AgtlO cDNA library
from A-15 cells was screened using an 800-base-pair (bp)
fragment from the tyrosine kinase portion of the partial bek
cDNA as a probe (6). Filters were hybridized as described
(5). The cDNAs were subcloned into pBluescript (Strata-
gene) and sequenced (21).
Abbreviations: FGF, fibroblast growth factor; bFGF, basic FGF;
aFGF, acidic FGF; K-FGF, Kaposi FGF; KGF, keratinocyte growth
factor; CHO, Chinese hamster ovary; HSPG, heparan sulfate pro-
teoglycan; IL-3, interleukin 3.
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Cell Lines and Transfections. CHO-DG44 cells were main-
tained as described (5). Cells were transfected by calcium
phosphate precipitation with a 3.7-kilobase (kb) bek cDNA in
p91023B vector (22). Positive clones were selected in medium
lacking hypoxanthine and thymidine (5). The stably trans-
fected 32D cells were isolated after electroporation with the
bek cDNA expressed in the pZip-NeoSV(X)1 vector (23). For
electroporation and selection, 5 x 106 cells were suspended
in 1 ml of cold phosphate-buffered saline (PBS) with 50 pug of
plasmid DNA in a Gene Pulser cuvette. The cuvette was
exposed to a 650-V impulse, 25 ,uF (Gene Pulser, Bio-Rad),
and kept on ice for 15 min. The cells were diluted in Iscove's
medium with 10% heat-inactivated fetal calf serum and IL-3
(10 units/ml). After 24 hr the cells were put in medium
containing geneticin (625 tkg/ml).
Binding Assays. Recombinant bFGF was iodinated as de-
scribed (24) (specific activity = 552 cpm/fmol). Recombinant
K-FGF was iodinated with 125I-labeled Bolton-Hunter re-
agent. The radioactive K-FGF was repurified on heparin-
Sepharose with 0.15% gelatin added to all buffers and had a
specific activity of 63 cpm/fmol. For Scatchard analysis,
clone CHO bek 3.7-5 was incubated with various concentra-
tions of 125I-bFGF from 0.25 to 10 ng/ml. Radioactive bFGF
bound to high-affinity receptors was quantitated as described
(5). Competition assays were performed as described (5).
Heparin (10 ,g/ml) was included in all assays (24).
Growth Curves. On day 0, 32D cells were washed with
serum-free medium and seeded at 1.5 x 105 cells per ml in
Iscove's medium with 10% heat-inactivated fetal calf serum,
and various growth factors were added as indicated. Cells
were counted in duplicate on days 2, 4, and 6.
Crosslinking to 32D Cells. 125I-bFGF was prepared by mild
chloramine-T treatment and purified over a Sephadex G-25
column. The specific activity of1251-bFGF was 4 x 104cpm/ng
(800 cpm/fmol). Cells (5 x 106) were washed twice in ice-cold
PBS and resuspended in 0.5 ml of binding medium (Iscove's
medium/0.15% gelatin) and 125I-bFGF at 10 ng/ml. Unlabeled
bFGF (1 jg/ml) and heparin (10 ,Lg/ml) were included as
indicated. The binding was performed for 2 hr at 4°C with
gentle agitation of samples. The cells were washed twice in
ice-cold PBS and crosslinked with disuccinimidyl suberate
(Pierce) (3 mM in PBS) for 30 min at room temperature.
Samples were loaded on an 8% polyacrylamide/SDS gel.
RESULTS
Cloning of the Murine bek cDNA Encoding a FGF Receptor.
The mouse BEK protein was originally identified as a tyro-
sine kinase in an expression cloning system using antiphos-
photyrosine antibodies to screen a liver cDNA library (6).
The partial sequence of BEK was 91% similar to the intra-
cellular catalytic domain ofthe chicken and human FLG FGF
receptor (2, 3). We used an 800-bp EcoRI fragment of bek as
a probe to isolate a full-length bek cDNA. Two clones that
had a 240-bp extension in the 5' direction were isolated and
the 240-bp EcoRI fragment (corresponding to amino acids
399-475 in Fig. 1) was used to screen several cDNA libraries.
A mouse brain cDNA library yielded a 2-kb EcoRI fragment
that overlapped perfectly with the entire probe and encoded
the amino terminus of the BEK protein.
The complete deduced protein sequence ofBEK is shown
in Fig. 1. Based on the homology to the FLG sequence, the
initiator methionine is located at position 607 of the cDNA
and is followed by a stretch of 20 hydrophobic amino acids
that could serve as a signal sequence. The 600 bp of 5'
untranslated leader sequence has fourATG codons that could
play a role in the regulation of BEK translation. The BEK
open reading frame of 821 amino acids is flanked by a 1.3-kb
3' untranslated region. The predicted protein shares 71%
homology with murine FLG and has all of the features of a
membrane-spanning tyrosine kinase receptor (25). In the
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FIG. 1. Deduced amino acid sequence of murine BEK protein.
The heavy underline is the transmembrane region. Cysteine residues
are marked by black squares and N-linked glycosylation sites are
marked by shaded ovals. The acidic region and conserved tyrosine
kinase motifs are highlighted. The kinase insert region is demarcated
by brackets.
356-amino acid extracellular portion, it has three immuno-
globulin-like loops similar to those of human BEK (7). Like
FLG, BEK has an acidic box (DDEDDTD) between the first
and second immunoglobulin loops, a characteristic motif of
the FGF receptor family. Although the overall homology
between BEK and FLG is high, it is lower (45%) in the highly
variable first immunoglobulin-like loop, which is dispensable
for FLG binding to aFGF, bFGF, or K-FGF (5, 16). Like the
other FGF receptors, BEK has a short (14 amino acid) kinase
insert region in the tyrosine kinase domain.
BEK Expression in Transfected CHO Cells. The bek cDNA
(3.7 kb) was cloned into the p91023B vector (22) and trans-
fected into dihydrofolate reductase-negative CHO cells
(clone DG44). These cells have very low numbers of FGF
receptors and do not express any RNA that hybridizes to bek
(data not shown). Dihydrofolate reductase-positive clones
were selected and tested for their ability to bind 125I-bFGF.
Clone CHO bek 3.7-5 was used for further characterization of
the receptor. When CHO bek 3.7-5 cells were exposed to
1251-bFGF or 125I-labeled K-FGF (125I-K-FGF) and a
crosslinking agent, a ligand-receptor complex of =160 kDa
was obtained (Fig. 2). The estimated size of the receptor(=140 kDa) is probably due to glycosylation. Higher molec-
ular mass forms were also observed that could represent
receptor oligomerization.
The dissociation constant of BEK for bFGF was deter-
mined by saturation binding analysis of clone CHO bek 3.7-5
with iodinated bFGF. Scatchard analysis of binding gives a
straight line, indicating a single class of binding sites on these
cells. From these data, bek 3.7-5 was calculated to have
40,000 receptors per cell with a Kd of 21 pM (Fig. 3). The Kd
was equal to that for our previously described CHO clone 3-4,
a CHO line expressing a similar number of two-immunoglob-
ulin-domain FLG receptors with a Kd of 17 pM for bFGF (5)
(Fig. 3).
To determine the relative affinities of bFGF, K-FGF, and
aFGF for the BEK receptor, competition curves were gen-
erated by measuring the ability of the unlabeled ligands to
displace labeled K-FGF. We had previously shown that
about 15 times more K-FGF than bFGF is needed to com-
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FIG. 2. Crosslinking of 1251-bFGF and "-'I-K-FGF to CHO cells
expressing the BEK receptor. CHO bek 3.7-5 cells were incubated
with the labeled ligand (10 ng/ml) in DMEM with 0.15% gelatin and
25 mM Hepes (pH 7.5). In the lanes marked + 50x bFGF and + 50x
KFGF, 500 ng of unlabeled ligand per ml was included. Molecular
masses are indicated in kDa. The rightmost lane in each panel was
loaded with three times more lysate than the left lane.
petitively inhibit the binding of 125I-bFGF to FLG-expressing
CHO cells (5), whereas aFGF is as efficient as bFGF (data not
shown). The curves in Fig. 4 show that on CHO bek 3.7-5
cells, K-FGF is as competent as bFGF or aFGF at displacing
the 125I-K-FGF. Similar results were obtained in the reverse
experiment using 125I-bFGF (data not shown).
In similar experiments we determined the ability of two
other members of the FGF family, FGF-5 and KGF, to
displace 125I-bFGF binding from clone CHO 3-4 (FLG-
expressing) cells and clone CHO bek 3.7-5 (BEK-expressing)
cells. The mitogenic activity of FGF-5 was tested on NIH 3T3
and BALB 3T3 cells to ensure that there was no loss of activity
ofthe growth factor. The mitogenic activity ofKGF was tested
on human cervical epithelial cells 183ATLL1 and 183BTLLI.
Neither KGF nor FGF-5 can displace 125I-bFGF from CHO
3-4 (FLG) cells (Fig. SA). On CHO bek 3.7-5 cells, KGF and
FGF-5 are unable to displace the labeled bFGF (Fig. SB). At
a concentration of 100 ng/ml bFGF displaced >90o of the
125I-bFGF bound to these cells, whereas KGF and FGF-5
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FIG. 3. Saturation binding analysis of 1251-bFGF on CHO 3-4 (flg)
and on CHO bek 3.7-5 cells. Cells were plated at 2 x 105 cells per
35-mm dish and incubated for 2 hr at 4°C with 1251-bFGF. Scatchard
analysis of the high-affinity binding is presented.
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FIG. 4. Competition assay. Competition for binding of 125I-K-
FGF (10 ng/ml) by bFGF, K-FGF, and aFGF on CHO bek 3.7-5
cells. All assays were performed in the presence of heparin (10
gg/ml).
displace, at best, 15% of the labeled ligand, indicating an
affinity at least 100-fold lower than that of bFGF.
Receptor Activation. To ensure that our cDNA clone en-
coded a functional receptor, we analyzed ligand-dependent
receptor tyrosine phosphorylation in CHO bek 3.7-5 cells.
Clone CHO bek 3.7-5 and CHO parental cells stimulated with
bFGF and K-FGF were extracted and tested by Western
analysis with antiphosphotyrosine antibodies. A band of
-140 kDa was seen in BEK clones treated with bFGF and
K-FGF at 10 ng/ml but not in those treated with platelet-
derived growth factor or in untreated cells (data not shown).
Thus FGF stimulation ofCHO cells expressing the FGF bek
receptor leads to the phosphorylation of a protein whose
molecular mass corresponds to the receptor that is
crosslinked to 125I-bFGF and 125I-K-FGF. The CHO bek
3.7-5 cells also show an increase in the rate ofDNA synthesis
in response to K-FGF or bFGF in a similar fashion to CHO
3-4 (fig) cells (data not shown). Additionally, CHO bek 3.7-5
cells exhibit an increase in cell number in response to bFGF
and K-FGF at 10 ng/ml in defined medium (data not shown).
Although the response is weak, with a cell doubling time up
to 40 hr, it is reproducible. The addition of heparin at 10
,ug/ml to the growth assay made no noticeable difference in
the growth curves.
bek Expression in Transfected 32D Cells. The bek cDNA
was cloned into the pZip-NeoSV(X)1 vector (23) and intro-
duced into 32D cells. The 32D cells are murine myeloid cells
that are negative for bek mRNA by Northern analysis and
express no detectable FGF receptors as determined by their
inability to bind 1251-bFGF (unpublished observations).
These cells are dependent on IL-3 for their proliferation and
survival (20). Clones expressing bek mRNA were tested for
their ability to bind 125I-bFGF. Two clones, 32D bek B3 and
32D bek B5, expressed about 3000 receptors per cell (data not
shown) and were used for further studies.
32D cells grow extremely poorly when the IL-3 concen-
tration is reduced to about 10% of the optimal concentration
for growth, and FGFs with or without heparin are not
mitogenic (see Fig. 7 and data not shown). When we tested
the ability of BEK-expressing 32D cells to grow in the
presence of bFGF or K-FGF in lowered IL-3 conditions, no
Biochemistry: Mansukhani et al.
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FIG. 5. Competition for binding of 125I-bFGF by bFGF, FGF-5, and KGF on CHO flg 3-4 cells (A) and on CHO bek 3.7-5 cells (B).
proliferation was observed even in the presence of very high
concentrations (1 ,ug/ml) ofthe growth factors. However, the
addition of heparin (50 ,ug/ml) made a dramatic difference
and the cells grew in the presence of K-FGF (50 ng/ml) plus
heparin as readily as in the presence of 10 units of IL-3 per
ml (Fig. 6). A similar effect was seen in the presence ofbFGF
plus heparin, although the growth was somewhat slower than
in the presence of 10 units of IL-3 per ml (Fig. 6). We have
been unable to sustain prolonged growth of these cells with
FGFs and heparin in the complete absence of IL-3. The
reasons for this situation are not clear but could result from
the existence of a specific IL-3 signal transduction pathway
that is necessary for cell survival.
To determine whether the heparin-dependent growth ofthe
32D bek cells was due to heparin-dependent binding of the
ligand to the BEK receptor, we performed crosslinking
experiments. 1251-bFGF was crosslinked to 32D bek B3 cells
in the presence and absence of heparin. A crosslinked band
of =160 kDa corresponding to the size of the ligand-receptor
complex was seen in the presence ofheparin. Although a faint
band was visible in the absence of heparin, this complex was
dramatically increased upon addition of heparin and was
competively inhibited by excess unlabeled bFGF (Fig. 7).
This band was absent in 32D parental cells that were similarly
treated (data not shown). 32D cells expressing the FLG
receptor showed identical results-i.e., they only grew in the
presence of FGFs and heparin-and the binding of iodinated
bFGF was almost completely heparin dependent (data not
shown). We did not detect any difference in the growth
responses of 32D fig and 32D bek cells to K-FGF. This result
is somewhat surprising given the lower affinity K-FGF has
for the FLG receptor. However, FLG-expressing CHO cells
also do not differ in their mitogenic response to K-FGF or
bFGF in spite of the difference in affinity for the two growth
factors (5).
DISCUSSION
We have demonstrated that the murine BEK receptor ex-
pressed in CHO cells is activated by three growth factors of
the FGF family, bFGF, aFGF, and K-FGF, whereas it does
not bind FGF-5 or KGF to any appreciable extent. This last
result is not surprising in the case of KGF, since a distinct
receptor has been identified for KGF from keratinocytes that
does not bind bFGF (17). In addition, KGF is known to act
specifically on epithelial cells and to have no effect on
fibroblast-like NIH 3T3 cells (26), which express BEK and
FLG. The lack of competition by FGF-5 is somewhat harder
to explain given that FGF-5 is mitogenic for NIH 3T3 and
BALB 3T3 cells. One possible explanation may be that
FGF-5 interacts with a BEK/FLG heterodimer and the CHO
cells used express only one or the other receptor. Alterna-
tively, FGF-5 may interact with another FGF receptor on
NIH 3T3 cells or be unable to interact with the endogenous
low-affinity receptors present in CHO cells. The affinity of
K-FGF for BEK is the same as bFGF, whereas the affinity
1 V7
* IL-3 IOU
+ IL-3 1.5U+hep+K-FGF
^ IL-3 l.5U+hep+bFGF
IL-3 1.SU+K-FGF
IL-3 1.5U+bFGF
- * IL-3 1.5U+hep
IL-3 15U
a)
.0
E 106-
105 1 ' ' '4
0 1 2 3 4 5 6 7
Days
FIG. 6. Growth curves of 32D bek B5 cells. Growth factors were
added at the following concentrations: K-FGF, 50 ng/ml; bFGF, 30
ng/ml; heparin (hep), 50 sg/ml. IL-3 units are units/ml. The same
results were obtained using 32D bek B3 cells.
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FIG. 7. Crosslinking of 25I-
bFGF to 32D bek B3 cells. In
each lane 125I-bFGF was added
at 10 ng/ml; + SOx bFGF = 500
ng of unlabeled bFGF per ml;
+ Hep = 10 ,ug of heparin per
ml. Molecular masses are indi-
cated in kDa.
of K-FGF for FLG is -15x lower than that of bFGF. Thus,
at present, BEK is the highest-affinity receptor known for
K-FGF.
Yayon et al. (18) have shown that the binding of bFGF to
FLG requires an obligatory interaction with HSPGs or low-
affinity receptors on the cell surface. Although heparan
sulfate has been shown to bind the FGFs and play indirect
roles in FGF function, such as stabilization and storage ofthe
growth factor (reviewed in ref. 1), its physiological signifi-
cance was probably underestimated until this direct demon-
stration of its obligatory role in bFGF binding to the FLG
receptor.
Since 32D cells grow in suspension and lack an extracel-
lular matrix, they are likely not to have the HSPGs that are
usually cell surface-matrix associated. In fact, these cells
have no detectable mRNA for syndecan, a low-affinity FGF
receptor that is a HSPG (27, 28) and is a potential candidate
molecule for the endogenous HSPG that cooperates with
FLG. The murine FLG receptor, expressed in another IL-3-
dependent myeloid cell line, FDC-P1, showed an absolute
requirement for heparin for receptor binding and growth (29).
Our studies with 32D cells demonstrate that the murine BEK
receptor, like FLG, requires the presence of HSPGs in order
to activate signal transduction and cell growth.
Thus, when the bek cDNA is introduced in CHO cells that
express HSPGs, it is capable ofbinding and ofbeing activated
by FGFs, in the absence of exogenous heparin. In 32D cells
that do not express low-affinity receptors (HSPG), BEK
cannot bind FGF and the cells do not proliferate unless
heparin is added to the medium. Presumably, heparin-bound
FGFs undergo a conformational change that is essential for
"presenting" the growth factor to the receptor. It should be
noted that a low level of binding to the BEK receptor can be
detected even in the absence of heparin (Fig. 7). The signif-
icance of this low-level binding, which is competitively
inhibited by unlabeled bFGF, is unclear, given the strict
growth dependence ofthese cells on added heparin. It may be
due to other low-affinity receptors present on 32D cells that
can partially substitute for the HSPGs and allow a weak
interaction between bFGF and the BEK receptor. Alterna-
tively, it is possible that FGFs can bind the BEK receptor
with low efficiency even without the conformational changes
induced by heparin or HSPGs but that this type of ligand-
receptor interaction is unstable. In any case, binding in the
absence of heparin is insufficient to activate the BEK mito-
genic response in hEK-expressing 32D cells. Although the
precise nature of the interaction between these three species
remains to be elucidated, it is evident that the biological
effects of the FGFs may be regulated at several levels-by
the presence of the growth factor, its affinity for the type of
tyrosine kinase receptor, and its interaction with the HSPG
components that are required to present the growth factor to
its receptors.
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